1. Home
  2. AGEN vs NIM Comparison

AGEN vs NIM Comparison

Compare AGEN & NIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGEN
  • NIM
  • Stock Information
  • Founded
  • AGEN 1994
  • NIM 1992
  • Country
  • AGEN United States
  • NIM United States
  • Employees
  • AGEN N/A
  • NIM N/A
  • Industry
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • NIM Trusts Except Educational Religious and Charitable
  • Sector
  • AGEN Health Care
  • NIM Finance
  • Exchange
  • AGEN Nasdaq
  • NIM Nasdaq
  • Market Cap
  • AGEN 142.8M
  • NIM 116.0M
  • IPO Year
  • AGEN 2000
  • NIM N/A
  • Fundamental
  • Price
  • AGEN $4.25
  • NIM $9.38
  • Analyst Decision
  • AGEN Buy
  • NIM
  • Analyst Count
  • AGEN 2
  • NIM 0
  • Target Price
  • AGEN $14.50
  • NIM N/A
  • AVG Volume (30 Days)
  • AGEN 431.2K
  • NIM 35.4K
  • Earning Date
  • AGEN 11-11-2025
  • NIM 01-01-0001
  • Dividend Yield
  • AGEN N/A
  • NIM 3.46%
  • EPS Growth
  • AGEN N/A
  • NIM N/A
  • EPS
  • AGEN N/A
  • NIM N/A
  • Revenue
  • AGEN $101,706,000.00
  • NIM N/A
  • Revenue This Year
  • AGEN $60.49
  • NIM N/A
  • Revenue Next Year
  • AGEN N/A
  • NIM N/A
  • P/E Ratio
  • AGEN N/A
  • NIM N/A
  • Revenue Growth
  • AGEN N/A
  • NIM N/A
  • 52 Week Low
  • AGEN $1.38
  • NIM $8.28
  • 52 Week High
  • AGEN $7.34
  • NIM $9.74
  • Technical
  • Relative Strength Index (RSI)
  • AGEN 45.64
  • NIM 65.78
  • Support Level
  • AGEN $3.78
  • NIM $9.27
  • Resistance Level
  • AGEN $4.38
  • NIM $9.40
  • Average True Range (ATR)
  • AGEN 0.24
  • NIM 0.07
  • MACD
  • AGEN 0.00
  • NIM 0.00
  • Stochastic Oscillator
  • AGEN 47.55
  • NIM 89.30

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About NIM Nuveen Select Maturities Municipal Fund

Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.

Share on Social Networks: